⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 1, 2022Journal of Thoracic DiseaseOpen Access

Comparison of laboratory parameters in mild vs. severe cases and died vs. survived patients with COVID-19: systematic review and meta-analysis

Budao Cao Xuefen Jing Yan Liu Rong Wen Cuifeng Wang

View Full Paper

Ask AI

Bookmark

Share

Abstract

In summary, current evidence show that those laboratory indicators are associated with the severity of COVID-19 and thus could be used as prognostic risk stratification of patients with COVID-19.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Cao et al. (2022) studied this question.

synapsesocial.com/papers/69dfee404fb243fc8e59246e https://doi.org/10.21037/jtd-22-345

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Landiolol for preventing postoperative atrial fibrillation: lessons from Japan for all?Journal of Thoracic Disease · Tue,
2Seven years of PARTNER 3: the evolution of a lifetime valve strategy, reassurance and residual uncertaintyJournal of Thoracic Disease · Tue,
3Air-Test for prediction of postoperative pulmonary complications after general anaesthesia: promise, performance and limitationsJournal of Thoracic Disease · Tue,
4Beyond the hazard ratio: machine learning and the future of personalized mitral valve repair counselingJournal of Thoracic Disease · Sat,
5Predicting mitral valve repair durability using artificial intelligence: promises, pitfalls, and the path to clinical practiceJournal of Thoracic Disease · Sat,

More from Journal of Thoracic Disease

Beta-blockers after myocardial infarction with preserved ejection fraction—reexamining established paradigms?Sat,
Managing mitral annular calcification—high-end robotic mitral valve repair for experienced surgeonsSat,
Machine learning in mitral valve repair: promise, precision, and the challenge of clinical translationSat,
When redo-transcatheter aortic valve replacement (TAVR) is not enough: self-expanding TAVR explant and the next frontier of lifetime valve managementSat,
Direct oral anticoagulants after surgical bioprosthetic valve replacement or mitral repair: reconciling valve and atrial fibrillation guidelinesSat,